Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

City of Hope

Status and phase

Active, not recruiting

Phase 1

Conditions

Stage I Prostate Cancer

Stage IIA Prostate Cancer

Stage III Prostate Cancer

Recurrent Prostate Cancer

Stage IIB Prostate Cancer

Treatments

Radiation: stereotactic body radiation therapy

Other: laboratory biomarker analysis

Procedure: quality-of-life assessment

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01923506

13257 (Other Identifier)

NCI-2013-01613 (Registry Identifier)

Details and patient eligibility

About

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Full description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) with an upper limit of 45 Gray (Gy) in 5 fractions, in the delivery of stereotactic body radiation therapy (SBRT) to the prostate fossa.

SECONDARY OBJECTIVES:

I. To assess acute and late toxicities from treatment.

II. To assess biochemical progression-free survival.

III. To collect prospective quality-of-life data related to bowel, urinary, and sexual health.

OUTLINE: This is a dose-escalation study.

Patients receive 5 fractions of SBRT over 1.5 weeks.

After completion of study treatment, patients are followed up at 90 days and then periodically for 3 years.

Enrollment

26 patients

Sex

Male

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

History of diagnosis of prostate cancer after undergoing prostatectomy
No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
Eastern Cooperative Oncology Group (ECOG) performance scale 0-2
Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable
Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry
PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion
All subjects must have the ability to understand and the willingness to sign a written informed consent

Exclusion criteria

Patients should not have any uncontrolled illness including ongoing or active infection
Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy
Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years
Study-specific exclusions:
- History of prior radiation to the pelvis
- History of uncontrolled inflammatory bowel disease
- Unable to comply with radiation therapy procedures
Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study